July 24, 2024 04:15 PM Eastern Daylight Time IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth. Edwards has entered into an agreement to acquire JenaValve Technology, […]
Tag: JenaValve
egnite, Inc. and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference
ALISO VIEJO, Calif.–(BUSINESS WIRE)–egnite, Inc., a leading digital health company for cardiovascular care, and JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, unveil a novel study presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24). The study, led by esteemed cardiologist […]
JenaValve’s Trilogy THV System Highlighted at CRT 2024
IRVINE, Calif., March 19, 2024 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from the Cardiovascular Research Technologies (CRT) Conference 2024. JenaValve’s Trilogy THV system, a TAVR system designed to treat patients with symptomatic, severe aortic regurgitation (ssAR), and symptomatic, severe aortic stenosis (ssAS), was featured in multiple scientific sessions highlighting the significant unmet need for devices to treat ssAR.
JenaValve Featured at the PCR London Valves 2023
IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from PCR London Valves 2023, a leading, annual global valve conference. The Trilogy THV system was featured in multiple case presentations and scientific sessions throughout […]
JenaValve Appoints Shlomi Nachman to Board of Directors
IRVINE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Shlomi Nachman, experienced cardiovascular industry executive, to its Board of Directors. Mr. Nachman has over 25 years of experience in the medical device […]
JenaValve Announces First Trilogy Heart Valve Systems Implanted in Asia
IRVINE, Calif., May 18, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the completion of the first two Trilogy Heart Valve System implantations in Asia. The two procedures were performed by Dr. Michael Lee and team at Queen […]
JenaValve Appoints Ken MacLeod, Ph.D. to Board of Directors
IRVINE, Calif., April 05, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Ken MacLeod, Ph.D., life sciences and medical device industry veteran, to its Board of Directors. Dr. MacLeod has over 35 years of […]
JenaValve Appoints Dan Dearen to Board of Directors
IRVINE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Dan Dearen, medical device industry executive, to its Board of Directors. Mr. Dearen has over 35 years of experience in the medical […]
JenaValve Appoints Duane Pinto, MD, MPH, as Chief Medical Officer
IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that Duane Pinto, MD, MPH, has been appointed as Chief Medical Officer. A leader in interventional cardiology, Dr. Pinto joins JenaValve following more than 20 years […]
JenaValve Completes Enrollment in the ALIGN-AR IDE Clinical Trial
Landmark ALIGN-AR Pivotal IDE Study Intended to Evaluate Use of the Trilogy™ Heart Valve System in Treatment of High Surgical Risk Patients with Symptomatic, Severe Aortic Regurgitation IRVINE, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today […]
Recent
Study at CRT 2025 Demonstrates Superiority of EggNest™ Complete Radiation Protection System Compared to Rampart Defender System in Total Room Protection
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
Popular
- No commented posts yet